Get the Stockscreener App
209.41
5.05%
-11.13
Pre-market:
210.00
0.59
+0.28%
Beigene Ltd Adr stock is traded at $209.41, with a volume of 501.74K.
It is down -5.05% in the last 24 hours and down -15.24% over the past month.
Founded in 2010 in Beijing and having listed on the Hong Kong exchange in 2018, BeiGene is a commercial-stage biotechnology company with global sales. It focuses on oncology therapeutics and differentiates itself from other companies with a contract research organization-free, or CRO-free strategy. BeiGene runs global clinical trials with its own team. As of 2024, its core drug is Brukinsa, a small molecule drug for various blood cancers that makes up more than 60% of BeiGene's revenue.
See More
Previous Close:
$220.54
Open:
$223.96
24h Volume:
501.74K
Relative Volume:
1.13
Market Cap:
$22.56B
Revenue:
$3.81B
Net Income/Loss:
$-644.79M
P/E Ratio:
-33.56
EPS:
-6.24
Net Cash Flow:
$-669.77M
1W Performance:
-22.74%
1M Performance:
-15.24%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$207.63
$225.80
1-Week Range:
$207.63
$276.00
52-Week Range:
$172.67
$287.88
Beigene Ltd Adr Stock (ONC) Company Profile
Name
Beigene Ltd Adr
Sector
Industry
Phone
13459494123
Address
C/O MOURANT GOVERNANCE SERVICES (CAYMAN), GRAND CAYMAN
Compare ONC with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ONC
Beigene Ltd Adr
|
209.41 | 22.56B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
472.37 | 121.44B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
556.81 | 60.87B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
548.93 | 33.48B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
224.32 | 29.03B | 2.25B | -278.16M | -42.59M | -2.17 |
Beigene Ltd Adr Stock (ONC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-07-25 | Initiated | RBC Capital Mkts | Outperform |
| Mar-03-25 | Upgrade | BofA Securities | Neutral → Buy |
| Dec-03-24 | Resumed | Morgan Stanley | Overweight |
| Sep-18-24 | Initiated | JMP Securities | Mkt Outperform |
| Feb-06-24 | Resumed | JP Morgan | Overweight |
| Sep-12-23 | Initiated | Macquarie | Outperform |
| Aug-17-23 | Initiated | Jefferies | Buy |
| Jul-17-23 | Initiated | Citigroup | Buy |
| Jun-30-23 | Downgrade | Bernstein | Outperform → Mkt Perform |
| Jan-12-23 | Initiated | Daiwa Securities | Buy |
| Oct-13-22 | Upgrade | Guggenheim | Neutral → Buy |
| Oct-13-22 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Aug-09-22 | Resumed | JP Morgan | Overweight |
| Mar-17-22 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Feb-07-22 | Initiated | Deutsche Bank | Buy |
| Oct-12-21 | Initiated | Bernstein | Outperform |
| Oct-06-21 | Upgrade | CLSA | Underperform → Buy |
| Mar-08-21 | Initiated | China Renaissance | Buy |
| Mar-01-21 | Downgrade | CLSA | Outperform → Underperform |
| Nov-09-20 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Nov-06-20 | Downgrade | Maxim Group | Buy → Hold |
| Nov-06-20 | Downgrade | Piper Sandler | Neutral → Underweight |
View All
Beigene Ltd Adr Stock (ONC) Latest News
RBC Capital sets BeiGene stock Outperform with $312 target By Investing.com - Investing.com South Africa
RBC Capital sets BeiGene stock Outperform with $312 target - Investing.com India
JMP reiterates BeiGene stock with $348 target despite trial halt - Investing.com India
Beigene’s president Wu Xiaobin sells $14.6 million in shares - Investing.com
BeiGene Discontinues Lung Cancer Drug Study After Interim Data Showed Limited Survival Benefit - Benzinga
Macquarie Prefers Biotechs Over CDMOs; Top Picks BEIGENE/ AKESO - AASTOCKS.com
Beigene director Wang Xiaodong sells $10.9 million in shares By Investing.com - Investing.com South Africa
Beigene director Wang Xiaodong sells $10.9 million in shares - Investing.com India
Beigene’s Wu Xiaobin anticipates $1.06 million from RMB shares sale - Investing.com
Bernstein raises BeiGene stock price target to $259 - Investing.com
BeiGene CEO John Oyler sells $10 million in shares - Investing.com India
Beigene CEO John Oyler sells $10.39 million in shares By Investing.com - Investing.com South Africa
Beigene CEO John Oyler sells shares worth $14.6 million - Investing.com India
BeiGene Stock: Top Executives Sell Shares Near Record High - Sharewise
Beigene CEO John Oyler sells shares worth $14.6 million By Investing.com - Investing.com South Africa
Beigene CEO John Oyler sells $10.39 million in shares - Investing.com
BeiGene Ltd. Sponsored ADR to Host Earnings Call - ACCESS Newswire
Beigene’s president Wu Xiaobin sells $13.6 million in shares - Investing.com
Beigene chair Wang Xiaodong sells shares worth over $2 million - Investing.com India
Beigene president sells economic interest in RMB shares for $1.16 million - Investing.com India
Beigene SVP sells $331,375 in American depositary shares - Investing.com India
BOCOMI: BEIGENE (06160.HK) Guides to Positive 2025 Operating Profit; Rating Kept at Buy - AASTOCKS.com
JPMorgan maintains BeiGene stock Overweight rating, $311 target - Investing.com India
Beigene SVP sells $331,375 in American depositary shares By Investing.com - Investing.com South Africa
JPMorgan maintains BeiGene stock Overweight rating, $311 target By Investing.com - Investing.com South Africa
BofA lifts BeiGene stock rating, raises target to $320 - Investing.com India
BofA lifts BeiGene stock rating, raises target to $320 By Investing.com - Investing.com South Africa
Beigene directors Julian and Felix Baker sell $190m in shares - Investing.com India
BeiGene gets FDA Orphan Drug Designation for sonrotocla - Investing.com
Guggenheim lifts BeiGene stock target to $348, maintains Buy rating - Investing.com India
Citizens JMP lifts BeiGene stock target to $348 on strong sales By Investing.com - Investing.com South Africa
Citizens JMP lifts BeiGene stock target to $348 on strong sales - Investing.com India
AASTOCKS Financial NewsBeiGene, Ltd. (ONC) - AASTOCKS.com
UBS Lifts BEIGENE (06160.HK) TP to $330, Rating Buy - AASTOCKS.com
BeiGene stock price target raised to $334 at TD Cowen By Investing.com - Investing.com South Africa
BeiGene stock price target raised to $334 at TD Cowen - Investing.com
BeiGene stock target raised to $308 on strong FY results - Investing.com India
BeiGene stock target raised to $308 on strong FY results By Investing.com - Investing.com South Africa
BeiGene beats Q4 expectations, sees strong 2025 revenue growth - Investing.com
BeiGene beats Q4 expectations, sees strong 2025 revenue growth By Investing.com - Investing.com South Africa
Beigene SVP sells shares worth $310,169 By Investing.com - Investing.com South Africa
Beigene SVP sells shares worth $310,169 - Investing.com India
Beigene's global head of R&D sells $1.29m in shares - Investing.com
Beigene, Ltd. (NASDAQ:ONC) COO Xiaobin Wu Sells 21,267 Shares - MarketBeat
BeiGene stock soars to 52-week high of $258.66 amid robust growth - Investing.com India
BeiGene stock soars to 52-week high of $258.66 amid robust growth By Investing.com - Investing.com South Africa
Beigene Ltd Adr Stock (ONC) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.20%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):